Le « Marijuana and Cannabinoids: A Neuroscience Research Summit » a été organisé par le National Institutes of Health (NIH, États-Unis) et a eu lieu les 22 et 23 mars 2016. Le sommet a mis l’accent sur les effets neurologiques et psychiatriques de la marijuana et autres cannabinoïdes, ainsi que sur le système endocannabinoïde. Le potentiel thérapeutique de même que les méfaits de la substance ont été discutés.
Sessions :
- Understanding the endocannabinoid system (jour 1)
- Brain development and function (jour 1)
- Psychosis, addiction, and alcohol interactions (jour 1)
- Therapeutic potential: Epilepsy and multiple sclerosis (jour 1)
- Psychomotor performance and detection (jour 2)
- Therapeutic potential: Pain and PTSD/Anxiety (jour 2)
- Policy Research: Challenges and Future Directions (jour 2)
Jour 1 (mardi 22 mars) : durée 6h30
Welcome and National Institutes of Health (NIH) Director remarks / Nora D. Volkow, M.D., Director, National Institute on Drug Abuse (NIDA) ; Walter J. Koroshetz, M.D., Director, National Institute of Neurological Disorders and Stroke (NINDS)
Understanding the endocannabinoid system / Co-Moderators: David Shurtleff, Ph.D., National Center for Complementary and Integrative Health (NCCIH) ; Aidan Hampson, Ph.D., NIDA
Speakers:
- 00:29:30 The endocannabinoid system – An introduction / Benjamin Cravatt, Ph.D., The Scripps Research Institute
- 00:51:10 Cannabinoid receptors: Where they are and what they do / Ken Mackie, M.D., Indiana University
- 01:13:50 Therapeutic potential of the cannabinoid system / Daniele Piomelli, Ph.D., University of California, Irvine
Brain development and function / Moderator: Steve Grant, Ph.D., NIDA
Speakers:
- 01:58:30 Does marijuana harm the brain? / Kent Hutchison, Ph.D., University of Colorado Boulder
- 02:18:00 Brain development and function: Adolescent marijuana use: Influence on learning, memory and brain changes / Susan Tapert, Ph.D., University of California, San Diego
- 02:36:50 Cannabis use and cognitive impairment / Madeline Meier, Ph.D., Arizona State University
03:20:10 Summit host remarks / Peggy Murray, Ph.D., National Institute on Alcohol Abuse and Alcoholism (NIAAA)
03:33:00 Office of National Drug Control Policy Remarks / Michael Botticelli, Director of National Drug Control Policy, Office of National Drug Control Policy (ONDCP)
Psychosis, addiction, and alcohol interactions / Co-Moderators: David Goldman, M.D., NIAAA ; Wilson M. Compton, M.D., M.P.E., NIDA
Speakers:
- 03:41:00 The association between cannabis use and psychosis: Clinical, epidemiological, and neuroscience perspectives / Anne Eden Evins, M.D., M.P.H., Massachusetts General Hospital
- 04:04:00 Addiction to cannabis phenomenology, prevalence, outcomes & probability / Alan Budney, Ph.D., Geisel School of Medicine at Dartmouth
- 04:23:30 Marijuana and alcohol interactions: Co-morbidity, consequences and mechanisms / Larry Parsons, Ph.D., The Scripps Research Institute
Therapeutic potential: Epilepsy and multiple sclerosis / Moderator: Alan L. Willard, Ph.D., NINDS
Speakers:
- 05:05:40 Mechanisms of cannabinoid signaling in epilepsy / Ivan Soltesz, Ph.D., Stanford University
- 05:34:50 Cannabinoids for treatment of pediatric epilepsy: The hype and the evidence / Amy Brooks-Kayal, M.D., Children’s Hospital Colorado
- 05:57:20 Multiple sclerosis and cannabinoids: Therapeutic potential / David Gloss, M.D., M.P.H., Charleston Area Medical Center
Jour 2 (mercredi 23 mars) : durée 5h30
Welcome and NIH Director remarks / Nora D. Volkow, M.D., Director, NIDA ; Francis S. Collins, M.D., Ph.D., Director, NIH
Psychomotor performance and detection / Moderator: Steve Gust, Ph.D., NIDA
Speaker :
- 00:19:20 Effects of cannabis on human psychomotor performance / Marilyn Huestis, Ph.D., University of Maryland School of Medicine
Therapeutic potential: Pain and PTSD/Anxiety / Co-Moderators: John Williamson, Ph.D., NCCIH ; Susan Borja, Ph.D., National Institute of Mental Health (NIMH)
Speakers:
- 00:56:00 Harnessing the therapeutic potential of the endocannabinoid signaling system to suppress pain / Andrea G. Hohmann, Ph.D., Indiana University
- 01:21:20 The therapeutic potential of cannabis in the treatment of neuropathic pain / Barth Wilsey, M.D., University of California, San Diego
- 01:45:40 Cannabinoids and the processing of fear and anxiety: Preclinical studies / Cecilia Hillard, Ph.D., Medical College of Wisconsin
- 02:10:43 What is the therapeutic potential of cannabis in PTSD & anxiety disorder treatment?: Evidence from human studies / Christine Rabinak, Ph.D., Wayne State University
Summit Host Remarks / Bruce Cuthbert, Ph.D., Acting Director, NIMH ; Josephine P. Briggs, M.D., Director, NCCIH
Policy research: Challenges and future directions / Co-Moderators: Susan Weiss, Ph.D., NIDA ; Michael Hilton, Ph.D., NIAAA
Speakers:
- 03:04:00 A Cannabis research agenda for policy design: What do we need to know? / Mark Kleiman, Ph.D., M.P.P., NYU Marron Institute of Urban Management, BOTEC Analysis Corporation
- 03:25:10 The effects of liberalizing marijuana policies on use & harms: Why research has not told us much / Rosalie Liccardo Pacula, Ph.D., RAND Corporation
- 03:54:50 Regulating retail marijuana: lessons learned from tobacco control / Stanton Glantz, Ph.D., University of California, San Francisco
- 04:20:50 Policy surveillance resources / Rosalie Liccardo Pacula, Ph.D., RAND Corporation
- 04:31:30 Recreational use of cannabis to be included in alcohol policy information system / Michael Hilton, Ph.D., NIAAA
Concluding Remarks / Robert M. Califf, M.D., Commissioner of Food and Drugs, U.S. Food and Drug Administration ; Nora D. Volkow, M.D., Director, NIDA